Cytokine interactions in mesenchymal stem cells from cord blood

Liu, Chi-Hsien; Hwang, Shiaw-Min

doi:10.1016/j.cyto.2005.11.003

Cited by 199 publications

(154 citation statements)

References 38 publications

Supporting

Mentioning

136

Contrasting

Unclassified

Order By: Relevance

“…Several researchers have observed that cytokines, such as IL-6, IL-8, MCP-1, Rantes, GRO and GRO-α, were constitutively expressed by both the bone marrow stem cells and umbilical cord blood stem cells. 31 Our results, obtained by challenging hUCBSC with glioma stem cells, are in agreement with the previously published results. Western blot and RT-PCR analyses conducted on the culture filtrates demonstrated increased expression levels of these cytokines along with the homing receptors CXCR4 and CD9 in hUCBSC and hUCBSC co-cultured xenograft lysates.…”

Section: Methodssupporting

confidence: 83%

The homing of human cord blood stem cells to sites of inflammation

2012

View full text Add to dashboard Cite

Section: Methodssupporting

confidence: 83%

The homing of human cord blood stem cells to sites of inflammation

2012

View full text Add to dashboard Cite

“…Among the cytokines investigated, we detected only IL-6 and IL-8. This is conceivable as they are constitutively expressed by hMSCs (19) and are potently stimulated after poly(I:C) treatment (Fig. 6) (18, 31).…”

Section: Discussionmentioning

confidence: 99%

Baculovirus Transduction of Mesenchymal Stem Cells Triggers the Toll-Like Receptor 3 Pathway

Chen

Shiah

et al. 2009

J Virol

View full text Add to dashboard Cite

“…In addition, IL-6, a hallmark of MSC activity, is vigorously secreted by MSCs following stimulation with IL-1b in a time-and dose-dependent manner, which requires the activation of the p38 MAPK and ERK pathways. 25 All of these data suggest that IL-1b could elicit the immunosuppressive properties of MSCs through IL-1R1. However, the mechanism through which IL-1b elicits these immunosuppressive properties is still unclear.…”

Section: Introductionmentioning

confidence: 96%

Pre-treatment with IL-1β enhances the efficacy of MSC transplantation in DSS-induced colitis

et al. 2012

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) have been used experimentally for treating inflammatory disorders, partly due to their immunosuppressive properties. Although interleukin-1b (IL-1b) is one of the most important inflammatory mediators, growing evidence indicates that IL-1b signaling elicits the immunosuppressive properties of MSCs. However, it remains unclear how IL-1b signaling accomplishes this activity. Here, we focus on the therapeutic efficacy of IL-1b-primed MSCs in the dextran sulfate sodium (DSS)-induced colitis model, in addition to the underlining mechanisms. We first found that IL-1b-primed MSCs, without any observable phenotype change in vitro, significantly attenuated the development of DSS-induced murine colitis. Moreover, IL-1b-primed MSCs modulated the balance of immune cells in the spleen and the mesenteric lymph nodes (MLNs) through elevating cyclooxygenase-2 (COX-2), IL-6 and IL-8 expression and influencing the polarization of peritoneal macrophages. Importantly, IL-1b-primed MSCs possessed an enhanced ability to migrate to the inflammatory site of the gut via upregulation of chemokine receptor type 4 (CXCR4) expression. In summary, IL-1b-primed MSCs have improved efficacy in treating DSS-induced colitis, which at least partly depends on their increased immunosuppressive capacities and enhanced migration ability.

show abstract

Cytokine interactions in mesenchymal stem cells from cord blood

Cited by 199 publications

References 38 publications

The homing of human cord blood stem cells to sites of inflammation

The homing of human cord blood stem cells to sites of inflammation

Baculovirus Transduction of Mesenchymal Stem Cells Triggers the Toll-Like Receptor 3 Pathway

Pre-treatment with IL-1β enhances the efficacy of MSC transplantation in DSS-induced colitis

Contact Info

Product

Resources

About